![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 02, 2020 12:31:19 PM
"The FDA provided feedback on clinical development plans for the evaluation of Brilacidin as a treatment for COVID-19. The Company is now incorporating this feedback and finalizing the trial protocol for its planned Phase 2, randomized, double-blind, placebo-controlled, multi-national study to evaluate the efficacy and safety of Brilacidin in hospitalized patients with COVID-19."
The use of non-USA European (my guess as to non-USA site) patients in the study means that the data acquired can be combined with the USA patient results to submit to the FDA for the advancement of B-CV into a P3. It also means that there can be no political shennanigans to slow-play the human trial in the USA and it will lower the overall costs. Smart move by mgt IMO as it may also lessen any anti-American feelings around the world that we could be fudging the data.
The patients receiving Brilacidin should see positive results within a day or two so there should be excellent feedback by the interim data date. As to timing, the article states
"Contract Research Organizations have been secured to expedite trial enrollment with many clinical sites expressing interest in participating in the study" so it is apparent that setting up the basics for the trial have already been established. All that remains are the patient enrollments and again the article says that should be very quick due to many sites expressing interest. Makes me believe we may see the start of trials (or at least a partial start at the non-USA site) by Dec. but that is strictly my WAG.
As to EUA, if B-CV shows efficacy on patients with severe symptoms one would assume that information would get MAJOR coverage to other hospitals around the world in a very expeditious manner.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM